Evoke Pharma Receives New Patent for GIMOTI Extending Market Exclusivity

Evoke Pharma Secures New U.S. Patent for GIMOTI

Evoke Pharma, Inc. (NASDAQ: EVOK), a dedicated player in the pharmaceutical landscape, has made significant strides with the announcement of a new U.S. patent for its leading product GIMOTI. This development marks a pivotal moment for the company, further solidifying its commitment to patients suffering from gastrointestinal (GI) disorders.

Details of the New Patent

The newly issued patent, numbered 12,377,064, particularly addresses the use of intranasal metoclopramide for patients who experience moderate to severe symptoms of gastroparesis. This patent, granted by the United States Patent and Trademark Office (USPTO), is a testament to the innovative approaches Evoke is taking in the treatment of GI diseases.

Extended Patent Exclusivity

One of the most significant aspects of this patent is the extension of its exclusivity period to November 2038, thanks to patent term adjustments (PTA). This extension prolongs GIMOTI’s market presence well beyond the previously expected expiration of patent protection in December 2036. Such prolongation is vital for a specialty pharmaceutical company focused on meeting the unique needs of patients.

Importance of GIMOTI for Patients

Matt D’Onofrio, the CEO of Evoke Pharma, expressed enthusiasm regarding the patent extension, emphasizing its importance as Gastroparesis Awareness Month unfolds. He indicated that this extension not only strengthens their intellectual property position but also reinforces the company's dedication to offering a non-oral treatment option for diabetic gastroparesis patients.

Addressing Gastroparesis Symptoms

The patent encompasses methods of alleviating symptoms linked to gastroparesis through the intranasal administration of metoclopramide. This promising approach caters to patients exhibiting specific symptom severity, a key aspect of Evoke’s ongoing development efforts. Additionally, the company is pursuing further claims via a continuation application to broaden the patent's scope.

Commitment to the Gastroparesis Community

Evoke Pharma is deeply committed to raising awareness about gastroparesis. During Gastroparesis Awareness Month, the company reaffirms its pledge to enhance the lives of those challenged by this debilitating condition. Their innovative treatments aim to address the significant challenges faced by millions suffering from GI disorders.

About GIMOTI

GIMOTI serves as a nasal spray solution that exerts its therapeutic effects for adults who grapple with fading GI function due to diabetic gastroparesis. This drug is particularly crucial as it offers an alternative for patients who struggle with the absorption of orally administered medications, as gastroparesis can delay gastric emptying.

Safety Considerations and Potential Risks

While GIMOTI has shown promise in the management of gastroparesis symptoms, it is essential for patients to be aware of its safety profile. The most significant risk associated with metoclopramide includes tardive dyskinesia (TD), a serious movement disorder that, if developed, can become irreversible.

Precautions and Contraindications

Patients should discontinue the use of GIMOTI if they observe any symptoms indicative of TD. Moreover, it should be noted that this treatment is not recommended for pediatric patients or those with certain hepatic or renal impairments, emphasizing the need for healthcare providers to assess individual patient risks carefully.

Looking Ahead

With this new patent in hand, Evoke Pharma is better poised to advance its mission of supporting patients with diabetic gastroparesis. This achievement highlights the company’s dedication to innovation and patient care, ensuring that those with debilitating symptoms have access to effective treatment options.

Investor and Media Inquiries

For those seeking more information about Evoke Pharma and its offerings, the company can be reached through their contact media representative, Daniel Kontoh-Boateng at DKB Partners. Interested parties can connect via telephone or email to discuss the exciting developments regarding GIMOTI and the company’s journey forward.

Frequently Asked Questions

What is GIMOTI?

GIMOTI is a nasal spray formulation of metoclopramide designed to treat acute and recurrent diabetic gastroparesis symptoms in adults.

How long is the exclusivity period for GIMOTI now?

The exclusivity period for GIMOTI has been extended to November 2038 due to recent patent adjustments.

What are the potential side effects of GIMOTI?

Potential side effects include dysgeusia, headache, fatigue, and a risk of tardive dyskinesia.

Why is the patent extension significant?

The patent extension allows Evoke Pharma to maintain market exclusivity, enabling further investment in the development and marketing of GIMOTI.

How does GIMOTI help gastroparesis patients?

GIMOTI provides a non-oral treatment alternative for diabetic gastroparesis patients, addressing issues related to delayed gastric emptying and medication absorption.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.